Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of LPM3480226 in Advanced Solid Tumors
NCT03844438Phase 1Unknown
- Sponsor
- Luye Pharma Group
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY01013 in solid tumor (advanced stage), sponsored by Luye Pharma Group. Primary endpoints: Safety and Tolerability of LPM3480226, Dose-Limiting Toxicity and 1 more. Status: unknown.
02
Drugs
LY01013
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03844438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844438.